Add-on Xeljanz controls disease as treatment for non-responding AS
Adding Xeljanz (tofacitinib) to treatment with biologic disease-modifying anti-rheumatic drugs (DMARDs) when these medications aren’t working well may help adults with ankylosing spondylitis (AS) keep their disease activity under control, a study suggests. Because the study included only a few patients, “further prospective randomized controlled trials with large…